

Publication Date: 27.02.2020 15:36

EANS-Voting Rights: Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

Notification of voting rights transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Overview

Notification made after deadline

Caution: In case of violations of major holdings notification rules, please pay attention to Section 137 BörseG 2018 (Suspension of voting rights)

1. Issuer: Marinomed Biotech AG

2. Reason for the notification:

Acquisition or disposal of voting rights

3. Person subject to notification obligation

Acting in concert agreement (Sec. 133 No. 1 BörseG 2018)

Name: Conseq Invest Akcie Nové Evropy

City: Dublin

Country: Ireland

Name: Conseq globální akciový účastnický fond

City: Prague

Country: Czech Republic

4. Name of shareholder(s):

5. Date on which the threshold was crossed or reached: 27.1.2020

6. Total positions

	% of voting rights attached to shares (7.A)	% of voting rights through financial/other instruments (7.B.1+_7.B.2)	Total of both in % (7.A + 7.B)	Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached	4.08 %	0.00 %	4.08 %	1,469,770
Position of previous notification (if applicable)				

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares				
	Number of voting rights		% of voting rights	
	Direct	Indirect (Sec	Direct	Indirect (Sec
ISIN Code	(Sec 130 BörseG	133 BörseG	(Sec 130 BörseG	133 BörseG
	2018)	2018)	2018)	2018)
AT0000831706		60,000		4.08 %
SUBTOTAL A		60,000		4.08 %

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG_2018				
Type of instrument	Expiration Date	Exercise Period	Number of voting rights that may be acquired if the instrument is exercised	% of voting rights
SUBTOTAL B.1				

B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG_2018					
Type of instrument	Expiration Date	Exercise Period	Physical / Cash Settlement	Number of voting rights	% of voting rights
			SUBTOTAL B.2		

8. Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the
financial/other instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

No.	Name	Directly controlled by No.	Shares held directly (%)	Financial/ other instruments held directly (%)	Total of both (%)
1	Jan Vedral		0.00 %	0.00 %	0.00 %
2	Conseq Investment Management, a.s.	1	0.00 %	0.00 %	0.00 %
3	Conseq Penzijní společnost, a.s.	2	0.00 %	0.00 %	0.00 %
	Conseq globální				

4	akciový úcastnický fond	3	2.33 %	0.00 %	2.33 %
5	Conseq _Invest_Plc Conseq		0.00 %	0.00 %	0.00 %
6	Invest Akcie _Nové_Evropy	5	1.75 %	0.00 %	1.75 %

9. In case of proxy voting

Date of general meeting: -

Voting rights after general meeting: - is equivalent to - voting rights.

10. Other comments:

Shares are held by two investment funds managed by investment companies as stated above acting in concert.

Further inquiry note:

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
<http://www.marinomed.com>

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
<http://www.metrum.at>

end of announcement

euro adhoc

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English